Image guided volumetric response during chemoradiotherapy for head and neck squamous cell carcinoma as a predictor of disease outcomes

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 37, Issue 4, 2016, Pages 304-310

  Davuluri, Rajayogesh ^a   Krase, Jeff M ^a   Cui, Haiyan ^a   Goyal, Uma D ^a   Cheung, Michael K ^a   Hsu, Charles C ^a   Yi, Sun K ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CANCER; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; MALE; MEGAVOLTAGE RADIATION; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; TOMOTHERAPY; TONGUE CANCER; TREATMENT FAILURE; CARCINOMA, SQUAMOUS CELL; DIAGNOSTIC IMAGING; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; X-RAY COMPUTED TOMOGRAPHY;

AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, IMAGE-GUIDED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84963963801     PISSN: 01960709     EISSN: 1532818X     Source Type: Journal    
DOI: 10.1016/j.amjoto.2016.03.003     Document Type: Article

References (24)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29, 10.3322/caac.21254.
2. [2] Pignon, J.-P., Maître, A. le, Maillard, E., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92 (2009), 4–14, 10.1016/j.radonc.2009.04.014.
3. [3] Kam, M.K., Leung, S.-F., Zee, B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25 (2007), 4873–4879.
4. [4] Chen, A.M., Farwell, D.G., Luu, Q., et al. Misses and near-misses after postoperative radiation therapy for head and neck cancer: Comparison of IMRT and non-IMRT techniques in the CT-simulation era. Head Neck 32 (2010), 1452–1459, 10.1002/hed.21343.
5. [5] Dawson, L.A., Sharpe, M.B., Image-guided radiotherapy: Rationale, benefits, and limitations. Lancet Oncol 7 (2006), 848–858.
6. [6] Den, R.B., Doemer, A., Kubicek, G., et al. Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: A prospective study. Int J Radiat Oncol 76 (2010), 1353–1359, 10.1016/j.ijrobp.2009.03.059.
7. [7] Duma, M.N., Kampfer, S., Wilkens, J.J., et al. Comparative analysis of an image-guided versus a non-image-guided setup approach in terms of delivered dose to the parotid glands in head-and-neck cancer IMRT. Int J Radiat Oncol 77 (2010), 1266–1273, 10.1016/j.ijrobp.2009.09.047.
8. [8] Kupelian, P.A., Ramsey, C., Meeks, S.L., et al. Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: Observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys 63 (2005), 1024–1028.
9. [9] Seibert, R.M., Ramsey, C.R., Hines, J.W., et al. A model for predicting lung cancer response to therapy. Int J Radiat Oncol 67 (2007), 601–609, 10.1016/j.ijrobp.2006.09.051.
10. [10] Bral, S., Duchateau, M., De Ridder, M., et al. Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC. Radiother Oncol 91 (2009), 438–442.
11. [11] Bishop, M., Al-Basheer, A., Greskovich, J., Adaptive Planning of Intensity Modulated Radiation Therapy for Head-and-Neck Cancers for Improved Accuracy of Delivered Dose in Patients With Clinically Significant Anatomical Change Due to Therapy. Proc Am Soc Radiat Oncol 54th Annu Meet ASTROs 54th Annu Meet, 84, 2012, S478, 10.1016/j.ijrobp.2012.07.1267.
12. [12] Schwartz, D.L., Garden, A.S., Thomas, J., et al. Adaptive radiotherapy for head-and-neck cancer: Initial clinical outcomes from a prospective trial. Int J Radiat Oncol 83 (2012), 986–993, 10.1016/j.ijrobp.2011.08.017.
13. [13] Tan, H.K., Giger, R., Auperin, A., et al. Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas—stratification for postsalvage survival. Head Neck 32 (2010), 139–147, 10.1002/hed.21159.
14. [14] Lefebvre, J.-L., Andry, G., Chevalier, D., et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 23 (2012), 2708–2714, 10.1093/annonc/mds065.
15. [15] Langer, C.J., Harris, J., Horwitz, E.M., et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group protocol 9911. J Clin Oncol 25 (2007), 4800–4805.
16. [16] Vermorken, J.B., Mesia, R., Rivera, F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008), 1116–1127.
17. [17] Gibson, M.K., Li, Y., Murphy, B., et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 23 (2005), 3562–3567, 10.1200/JCO.2005.01.057.
18. [18] Argiris, A., Li, Y., Murphy, B.A., et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22 (2004), 262–268, 10.1200/JCO.2004.08.039.
19. [19] Brizel, D.M., Prosnitz, R.G., Hunter, S., et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 58 (2004), 1418–1423, 10.1016/j.ijrobp.2003.09.004.
20. [20] Machtay, M., Moughan, J., Trotti, A., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol Off J Am Soc Clin Oncol 26 (2008), 3582–3589, 10.1200/JCO.2007.14.8841.
21. [21] Liauw, S.L., Mancuso, A.A., Amdur, R.J., et al. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: The use of computed tomography to manage the neck. J Clin Oncol 24 (2006), 1421–1427, 10.1200/JCO.2005.04.6052.
22. [22] Yao, M., Graham, M.M., Hoffman, H.T., et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 59 (2004), 1001–1010, 10.1016/j.ijrobp.2004.01.040.
23. [23] Bral, S., Duchateau, M., De Ridder, M., et al. Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC. Radiother Oncol J Eur Soc Ther Radiol Oncol 91 (2009), 438–442, 10.1016/j.radonc.2009.03.015.
24. [24] Hara, W., Loo, B.W., Goffinet, D.R., et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 71 (2008), 393–400, 10.1016/j.ijrobp.2007.10.027.